Akebia Therapeutics
AKBA
157 hedge funds and large institutions have $100M invested in Akebia Therapeutics in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 55 reducing their positions, and 38 closing their positions.
57% more call options, than puts
Call options by funds: $726K | Put options by funds: $463K
4% more capital inflows, than outflows
Capital inflows: $17.4M | Capital outflows: $16.7M
0.98% less ownership
Funds ownership: 40.24% → 39.26% (-0.98%)
8% less funds holding
Funds holding: 170 → 157 (-13)
27% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 55
42% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.34M |
| 2 |
Two Sigma Investments
New York
|
+$3.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.43M |
| 4 |
BlackRock
New York
|
+$1.18M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.07M |
| 2 |
Millennium Management
New York
|
-$1.52M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.36M |
| 4 |
Citigroup
New York
|
-$1.19M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.07M |
AKBA Hedge Fund Activity: Q3 2026 in Review
157 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2026, worth a combined $100M — down 19% from $123M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of AKBA and 22 opened new positions — a net loss of 16 holders — while 55 trimmed existing stakes and 40 added.
The largest buyer was Acadian Asset Management, adding an estimated $5.34M. The largest seller was AQR Capital Management, cutting an estimated $3.07M.
- 157 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2026, down from 170 in Q2 2026.
- Funds reported $100M of Akebia Therapeutics stock for Q3 2026, down 19% quarter-over-quarter.
- 22 funds opened new Akebia Therapeutics positions in Q3 2026 and 38 closed out, a net change of -16 holders.
- The largest Akebia Therapeutics buyer in Q3 2026 was Acadian Asset Management, an estimated $5.34M added.
- The largest Akebia Therapeutics seller in Q3 2026 was AQR Capital Management, an estimated $3.07M sold.
Based on aggregated 13F filings for Q3 2026.